Tbnet — Collaborative research on tuberculosis in Europe

Giehl, Claudia; Lange, Christoph; Duarte, Raquel; Bothamley, Graham; Gerlach, Christina; Cirillo, Daniela María; Wagner, Dirk; Kampmann, Beate; Goletti, Delia; Juers, T.; Sester, Martina

doi:10.1556/eujmi.2.2012.4.4

Cited by 16 publications

(9 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TBNET is a European consortium for clinical research in the field of TB ( 9 ). This study was conducted at 23 TBNET sites in 16 countries in Europe: 2 with a high (>100 cases/100,000 persons) incidence of TB, 4 with an intermediate (20–100 cases/100,000 persons) incidence, and 10 with a low (<20 cases/100,000 persons) incidence (Figure).…”

Section: Methodsmentioning

confidence: 99%

Multidrug-Resistant Tuberculosis in Europe, 2010–2011

Günther

Leth

Alexandru³

et al. 2015

Emerg. Infect. Dis.

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Multidrug-Resistant Tuberculosis in Europe, 2010–2011

Günther

Leth

Alexandru³

et al. 2015

Emerg. Infect. Dis.

Self Cite

View full text Add to dashboard Cite

show abstract

“…TBNET is a network to promote clinically oriented research in the field of TB in Europe, through collaborative research [7]. Physicians in the network collected data during February-March 2013 through hospital pharmacies, dispensaries or, where applicable, through national TB programmes.…”

Section: Methodsmentioning

confidence: 99%

Availability, price and affordability of anti-tuberculosis drugs in Europe: a TBNET survey

et al. 2014

Self Cite

View full text Add to dashboard Cite

Data on availability and cost of anti-tuberculosis (TB) drugs in relation to affordability at national level are scarce.We performed a cross-sectional study on availability and cost of anti-TB drugs at major TB-reference centres in 37 European countries. Costs of standardised treatment regimens used for pan-sensitive TB, multidrug-resistant (MDR) TB, pre-extensively drug-resistant (XDR) TB, and XDR-TB were compared using a purchasing power analysis. Affordability was evaluated in relation to monthly national gross domestic products per capita (GDP).At least one second-line injectable and either moxifloxacin or levofloxacin were available in all countries. Linezolid and clofazimine were available in 79% and 46% of the countries, respectively. Drug cost for XDR-TB was three-times more expensive than those for MDR-TB. The average price of treatment for pan-sensitive TB represented a maximum of 8.5% of the monthly GDP across countries, while for standard MDR-TB treatment this was <30% in only six countries and more than 100% in four countries. Treatment of XDR-TB represented more than 100% of a month's GDP in all countries where the regimen was available.High cost and limited availability of drugs for treatment of drug-resistant TB, particularly beyond resistance to first-line drugs, are a major impediment to successful TB control in Europe. @ERSpublications Limited availability and high cost of drugs hamper the treatment of drug-resistant tuberculosis in Europe

show abstract

“…The Tuberculosis Network European Trialsgroup (TBNET; http://www.tb-net.org/ ) is made up of >650 physicians who wish to participate in clinical trials in tuberculosis and who therefore aim to maintain accurate data regarding their patients [ 15 ]. A survey of TBNET members was conducted to review clinical records of those with tuberculosis from 1 September 2008 to 31 August 2013 if possible, or at least for a period of one year or more.…”

Section: Methodsmentioning

confidence: 99%

Pregnancy in patients with tuberculosis: a TBNET cross-sectional survey

Bothamley

Ehlers

Salonka

et al. 2016

BMC Pregnancy Childbirth

View full text Add to dashboard Cite

BackgroundObjectives: To determine whether the incidence of tuberculosis with pregnancy is more common than would be expected from the crude birth rate; to see whether there is significant delay in the diagnosis of tuberculosis during pregnancy.MethodDesign: A cross-sectional survey. Setting: 13 tuberculosis clinics within different European countries and the USA. Population/sample: All patients with tuberculosis seen at these clinics for a period > 1 year. Instrument: Questionnaire survey based on continuous data collection. Main outcome measures: number and proportion of women with tuberculosis who were pregnant; timing of diagnosis in relation to pregnancy, including those who were pregnant or delivered in the 3 months prior to the diagnosis of TB and those who developed TB within 3 months after delivery.ResultsPregnancy occurred in 224 (1.5 %) of 15,217 TB patients and followed the expected rate predicted from the crude birth rate for the clinic populations. TB was diagnosed more commonly in the 3 months after delivery (n = 103) than during pregnancy (n = 68; χ 2 = 25.1, P < 0.001).ConclusionsTB is diagnosed more frequently after delivery, despite variations in local TB incidence and healthcare systems.

show abstract

Tbnet — Collaborative research on tuberculosis in Europe

Cited by 16 publications

References 29 publications

Multidrug-Resistant Tuberculosis in Europe, 2010–2011

Multidrug-Resistant Tuberculosis in Europe, 2010–2011

Availability, price and affordability of anti-tuberculosis drugs in Europe: a TBNET survey

Pregnancy in patients with tuberculosis: a TBNET cross-sectional survey

Contact Info

Product

Resources

About